Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for adjuvant treatment of resected non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 3852

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
13 May 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
23 March 2021 - 22 April 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
23 March 2021 In progress. DHSC referral received: 05/08/2020

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance